Figure 2

Progression-free survival (PFS) and overall survival (OS) of patients with CD20-negative diffuse large B-cell lymphoma (DLBCL) and CD20-positive DLBCL. (A): PFS of patients with CD20-negative DLBCL (n = 21, dotted line) and patients with CD20-positive DLBCL (n = 63, solid line). (B): OS of patients with CD20-negative DLBCL (n = 21, dotted line) and patients with CD20-positive DLBCL (n = 63, solid line).